• Pyxis Oncology published a corporate deck detailing an interim clinical update for micvotabart pelidotin (MICVO), an EDB+FN-targeting antibody-drug conjugate.
• In 2L+ recurrent or metastatic HNSCC, the 5.4 mg/kg Q3W dose-capped subgroup showed 36% confirmed ORR and 94% disease control.
• Median progression-free survival was 6.2 months; 12-month overall survival probability was 79% in the dose-capped analysis.
• Management highlighted a Phase 3 start planned for mid-2027; dose capping was adopted to reduce toxicity in higher-weight patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.